Clinical trials: Diabetes Mellitus II
Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus
Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus
Prospective, single center, double-blind, randomized pharmacodynamic experimental study. The study will enroll 150 subjects with ASCVD on optimal statin therapy as per physician and Diabetes Mellitus (DM) undergoing elective…
- Conditions
- Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
- Trial name
- ISS-DMII (NCT03258281)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Inova Health Care Services
Diabetes Mellitus, Type 2
4 Weeks Treatment of Type II Diabetic Patients With BI 44847
The primary objective of the current study is to investigate the safety and tolerability of BI 44847 in male and female patients with type 2 diabetes following oral administration of repeated doses of 100 mg b.i.d, 400 mg b.i.d.
- Trial name
- NCT00558909
- Testing
- BI 44847
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Type II Diabetes
Supplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-Diabetes
Investigators research team conducted a previous human clinical trial of brown algae and conducted liver and metabolic indicators of brown algae to improve nonalcoholic fatty liver disease, and found brown algae extract…
- Trial name
- NCT04715776
- Testing
- Brown seaweed
- Where
- Taiwan
- Volunteers
- 106 people
- Sponsor
- Taipei Medical University WanFang Hospital
Diabetic Polyneuropathy
Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
The primary objectives of the study are to evaluate the efficacy and safety of three doses of MCC-257 in patients with mild to moderate diabetic polyneuropathy
- Trial name
- NCT00307749
- Testing
- MCC-257
- Volunteers
- 420 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2…
- Trial name
- NCT06688123
- Testing
- SHR-3167, Insulin glargine
- Where
- 2 sites in China
- Volunteers
- 275 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.5/1000 mg in healthy male volunteers.
- Trial name
- NCT02565368
- Testing
- Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg, CKD-395 0.5/1000mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type II Diabetes, Periodontal Disease
Periodontal Treatment Response in Type II Diabetic Patients
Diabetes mellitus affects > 171 million people worldwide, with type II diabetes being the most prevalent, affecting 85-95% of the diabetic population.
- Trial name
- NCT01881074
- Testing
- Triclosan containing toothpaste, Non-triclosan containing toothpaste
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type II
Detection of Diffuse Scar in Patients With Diabetes
People with diabetes are at an increased risk of heart attacks and heart failure, and it is important to be able to treat people with diabetes who are at risk for heart disease to prevent these outcomes.
- Trial name
- NCT01794091
- Testing
- Eplerenone
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
The TANTALUS® II for the Treatment of Type 2 Diabetes
Evaluation of the safety and efficacy of gastric contractility modulation (GCM) stimulation using the TANTALUS System in the improvement of glycemic control measured by changes in HbA1c.
- Trial name
- Crossover (NCT01303302)
- Testing
- Tantalus System
- Where
- 7 sites in Austria, Germany and 2 more
- Volunteers
- 51 people
- Sponsor
- MetaCure (USA), Inc.
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes Mellitus
Using Technology to Share Fitness Goals and Results to Improve Diabetes Outcomes
The investigators will recruit DoD beneficiaries, aged 18 years or older and diagnosed as being Type II diabetic. Patients will be randomized into one of two groups.
- Trial name
- NCT02761018
- Testing
- Behavioral: Fitness Tracker, Fitness Tracker
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Mike O'Callaghan Military Hospital
Type II Diabetes Mellitus
cfMSC Therapy for Diabetes
The purpose of this study is to assess the feasibility, safety and clinical efficacy of the novel clonal fetal mesenchymal stem cell (cfMSC) therapy in patients with type II diabetes mellitus.
- Trial name
- NCT07495956
- Testing
- cfMSC therapy for diabetes
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Proteinuria, Hypertension
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.
- Conditions
- Proteinuria, Hypertension, Type II Diabetes
- Trial name
- NCT01804777
- Testing
- Amiloride, HCTZ
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of New Mexico
Diabetic Foot Ulcers
Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer
This is an open-label, active-control, multicentre, parallel group, randomised and dose-finding efficacy and safety study. Compare the efficacy and safety of BioChaperone PDGF-BB applied at 12.5 µg/cm² every two days for up to 20…
- Trial name
- NCT01098357
- Testing
- Biochaperone PDGF-BB Low dose, Biochaperone PDGF-BB High dose, Regranex
- Where
- 7 sites in India
- Volunteers
- 192 people
- Sponsor
- Virchow Group
Peripheral Artery Disease
Important Parameters of NIR-II Imaging in the Early Diagnosis of Lower Extremity Peripheral Artery Disease
Lower extremity peripheral artery disease (PAD) is a growing global health problem. New ways have been explored to diagnose PAD in recent years, such as the second near-infrared region (NIR-II, 900-1,880 nm wavelengths) imaging.
- Trial name
- NCT06565819
- Testing
- The second near-infrared region (NIR-II) imaging for lower extremity peripheral artery disease (PAD)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Yijie Ning
Type 2 Diabetes Mellitus (T2DM)
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2…
- Trial name
- NCT07055386
- Testing
- GZR102, GZR18
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Vascular Diseases, Diabetes
Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II)
The purpose of this trial is to find out the appropriate way to treat DM patients with critical limb ischemia. This trial includes two parts.
- Trial name
- DCLI-II (NCT01173094)
- Testing
- Percutaneous Transluminal Angioplasty, below-knee arterial bypass
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Peking Union Medical College Hospital
Diabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
This study is a 2-part open-label, randomized, crossover, multicenter, non-therapeutic Phase II study to investigate the presence of pancreatic exocrine insufficiency (PEI) in patients with Type 2 diabetes mellitus (T2DM), and to…
- Trial name
- PRECISE (NCT02370537)
- Testing
- Epanova® (omega-3 carboxylic acids), Omacor® (omega-3-acid ethyl esters)
- Where
- 22 sites in Denmark, Hungary and 4 more
- Volunteers
- 490 people
- Sponsor
- AstraZeneca